| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sharebased compensation | 556 | 609 | 611 | 1,781 |
| Amortization of premium and discount on marketable securities, net | NaN | 0 | 0 | 129 |
| Impairment of long-lived assets | NaN | 3,508 | 2,637 | NaN |
| Other non-cash items | NaN | 0 | 0 | 14 |
| Net gain on lease termination | 633 | NaN | NaN | NaN |
| Prepaid expenses and other current assets, and other assets | 53 | -1,034 | 235 | 571 |
| Depreciation Depletion And Amortization | 129 | 177 | 181 | 370 |
| Prepaid research and development | -107 | -490 | 33 | 66 |
| Non-refundable sublicense and transition services payments received | NaN | 0 | 2,500 | 1,515 |
| Right of use assets and operating lease liabilities | 4,973 | 127 | 122 | 215 |
| Accounts payable | 197 | 161 | 66 | 1,653 |
| Accrued expenses and other current liabilities | -758 | 652 | -72 | -2,634 |
| Net Income Loss | -7,600 | -12,983 | -32,539 | NaN |
| Net gain on lease termination | 600 | NaN | NaN | NaN |
| Net cash provided by (used in) operating activities | -12,987 | -6,479 | -4,853 | -20,177 |
| Sale of property and equipment and other assets | NaN | NaN | 0 | 1,170 |
| Sales or maturities of marketable securities | NaN | 0 | 0 | 39,046 |
| Sales of property and equipment and other assets | 20 | 1,170 | NaN | NaN |
| Net cash provided by (used in) investing activities | 20 | 0 | 0 | 40,216 |
| Proceeds from the issuance of common stock under employee stock purchase plan | NaN | 9 | 0 | 14 |
| Net cash provided by (used in) financing activities | NaN | 9 | 0 | 14 |
| Net increase (decrease) in cash and cash equivalents | -12,967 | NaN | NaN | NaN |
| Net increase (decrease) in cash and cash equivalents | -12,967 | -6,470 | -4,853 | 20,053 |
| Cash and cash equivalents at beginning of period | 46,303 | 52,773 | 37,573 | NaN |
| Cash and cash equivalents at end of period | 33,336 | 46,303 | 52,773 | NaN |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)